Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]fluorobenzoyl-doxorubicin
- Development stage
- Preclinical
- Lead developer
- University of California, San Francisco
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intra-arterial, Intravenous
01
Overview
[18F]fluorobenzoyl-doxorubicin (also known as [18F]FB-Dox) is a fluorine-18 radiolabeled analog of the chemotherapeutic drug doxorubicin. Developed by researchers at the University of California, San Francisco (UCSF), it serves as a positron emission tomography (PET) imaging tracer and diagnostic tool. It is primarily used to evaluate the binding efficiency of endovascular ChemoFilter devices designed to capture excess chemotherapeutics during intra-arterial chemotherapy (such as for hepatocellular carcinoma) and to assess the in vivo biodistribution and pharmacokinetics of doxorubicin (e.g., following blood-brain barrier disruption or during hepatic intra-arterial chemotherapy).
- Other names
- [18F]FB-DOX[18F]fluorobenzoyl doxorubicin18F-FB-Dox18F-fluorobenzoyl-doxorubicindoxorubicin-[18F]fluorobenzamidefluorine-18 fluorobenzoyl-doxorubicinfluorine18 fluorobenzoyl-doxorubicinfluorine 18 fluorobenzoyl-doxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)TOP2B (DNA topoisomerase II beta)
Beyond the preview
Go deeper on [18F]fluorobenzoyl-doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]fluorobenzoyl-doxorubicin.